HAYWARD, Calif.--(BUSINESS WIRE)--Mar. 21, 2018--
Pulse Biosciences, Inc. (NASDAQ: PLSE), a medical technology company
developing a proprietary therapeutic tissue treatment based on its
Nano-Pulse Stimulation (NPS) platform, today announced that the
Compensation Committee of the company’s Board of Directors granted
non-qualified stock options covering an aggregate of 50,000 shares of
Pulse Biosciences common stock to five new employees under the Pulse
Biosciences 2017 Inducement Equity Incentive Plan on March 19, 2018.
The 2017 Inducement Equity Incentive Plan is used exclusively to grant
equity awards to individuals who were not previously an employee or
non-employee director of Pulse Biosciences as an inducement material to
such individual's entering into employment with Pulse Biosciences in
accordance with Nasdaq Marketplace Rule 5635(c)(4).
The options have an exercise price of $14.52 per share, which is equal
to the closing price of Pulse Biosciences common stock on March 19,
2018. Each option will vest and become exercisable as to 25% of the
shares on the first anniversary of the recipient’s start date, and will
vest and become exercisable as to the remaining 75% of the shares in 36
equal monthly installments following the first anniversary of the
recipient’s start date, subject to each such employee’s continued
employment with Pulse Biosciences on these vesting dates. The options
are subject to the terms and conditions of the 2017 Inducement Equity
Incentive Plan and the award agreements entered into with each recipient.
About Pulse Biosciences
Pulse Biosciences is a clinical stage electroceutical, an electrical
energy based therapeutic, company pursuing commercial applications of
its proprietary Nano-Pulse Stimulation (NPS) technology. NPS is a
non-thermal, precise, focal, drug-free tissue treatment technology
utilizing nanosecond (billionth of a second) range pulsed electric
fields that directly affect the cell membrane and intracellular
structures and initiates programmed cell death in treated cells. The
unique ability of NPS to initiate cell death has the potential to
significantly benefit patients in a wide variety of medical applications
including applications in immuno-oncology and dermatology, and other
potential applications we may pursue in the future. The initiation of
programmed cell death by NPS results in a minimal inflammatory response,
which improves healing outcomes and supports the replacement of treated
tissue cells with healthy tissue cells. In cancerous lesions, NPS has
been shown in preclinical models to induce immunogenic cell death (ICD),
which exposes the unique antigens of the treated cells to the immune
system and enrolls immune system cells, such as cytotoxic T-cells to
mount an adaptive immune response. Pulse Biosciences is investigating a
variety of applications for its technology that exploits the
technology’s unique biologic effect, including immuno-oncology and
dermatology. More information is available at www.pulsebiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180321006078/en/
Source: Pulse Biosciences, Inc.
Pulse Biosciences, Inc.
Investors:
Brian Dow
Sr.
Vice President and Chief Financial Officer
IR@pulsebiosciences.com
or
The
Trout Group
Mike Zanoni, 646-378-2924
mzanoni@troutgroup.com
or
Media:
Sam
Brown, Inc.
Christy Curran, 615-414-8668
christycurran@sambrown.com
